Our Q4 2023 results will be published on March 7, 2024, at 7 a.m. (CET). Our press conference will take place at 10:00 a.m. (CET), and the conference call for analysts at 2 p.m. (CET).
Welcome to our Investor Relations
5 reasons to investWe develop products and solutions that make life better – and have been successfully doing so for more than 350 years. And when you’ve prospered for centuries as we have, you must have done a few things right.Read More
SustainabilityFor us, scientific progress and responsible entrepreneurship go hand in hand, enabling us to create a sustainable future for everyoneRead more
Reports & FinancialsMerck KGaA, Darmstadt, Germany, keeps growing profitably. The excellent performance of our business shows that we are on the right track. See for yourself in our comprehensive reports and financials.Read More
26 Apr 2024
The Annual General Meeting of Merck KGaA, Darmstadt, Germany will take place on April 26, 2024.
Investor Related NewsView All News
Merck KGaA, Darmstadt, Germany, today announced a license agreement with Abbisko Therapeutics for pimicotinib (ABSK021).
We successfully integrated p-Chip's microtransponder technology as a crypto-anchor into a cyber-physical trust framework solution developed by us.
Further develops its biosafety testing laboratories for local demand; New labs complete 2nd phase of company's €29 million Biologics Testing Center.